<
AI
Automation
Science
Innovation
Open Source
Blockchain
Social Media
Startups
Culture
Cloud
>

Destination
Hims & Hers strikes a deal with Novo Nordisk to sell Wegovy — and the stock soars 28%

Telehealth company Hims & Hers (HIMS) announced Tuesday that it will begin selling Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy.Read more... [...]

Discover Copy
Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be next

Hims & Hers (HIMS) is expanding its playbook across the Atlantic — the U.S.-based telehealth company announced Tuesday that it will acquire European telehealth platform Zava. The acquisition gro [...]

Match Score: 165.49

Destination
Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.Read more... [...]

Match Score: 148.59

qz
Hims & Hers will get to sell Ozempic. Like, real Ozempic. The stock soars 50%

Novo Nordisk and Hims had clashed on and off for months as the telehealth firm marketed compounded versions of Novo's blockbuster GLP-1 drug Wegovy [...]

Match Score: 121.97

Destination
Hims & Hers stock tumbles as the FDA issues a warning about 'unapproved' weight loss drugs

Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company braces for big regulatory shifts in the weight-loss drug industry.Read more. [...]

Match Score: 115.65

thenextweb
Hacking group claims it breached Novo Nordisk and demanded $25m

A cyber-extortion group calling itself FulcrumSec said on Monday that it had stolen roughly 1.3 terabytes of data from Novo Nordisk, the Danish maker of the weight-loss drugs Wegovy and Ozempic, and h [...]

Match Score: 99.28

Destination
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]

Match Score: 92.47

Destination
Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and investment returns in 2024.Read more... [...]

Match Score: 92.20

thenextweb
Novo Nordisk hands shelved Parkinson’s cell therapy to Zuckerberg-backed Cellular Intelligence

Novo will take an equity stake in Cellular Intelligence and is in line for future milestone payments and royalties. The startup plans to apply its AI platform to STEM-PD, a stem-cell-derived treatment [...]

Match Score: 90.71

Destination
Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year

Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for the blockbuster drugs Ozempic and Wegovy, the company [...]

Match Score: 90.61